NanoMedicine Labs
NanoMedicine Labs Raises $460M Series C to Transform Healthcare
NanoMedicine Labs
Breakthrough nanoscale drug delivery systems enabling targeted cancer treatment with 95% reduced side effects.
About the Funding
NanoMedicine Labs has successfully raised $460M in a Series C funding round, bringing their total valuation to $5.8B. This significant investment will fuel the company's mission to advance phase iii clinical trials, scale manufacturing capabilities, and expand pipeline to rare diseases.
Use of Funds
Advance Phase III clinical trials, scale manufacturing capabilities, and expand pipeline to rare diseases
Company Overview
Breakthrough nanoscale drug delivery systems enabling targeted cancer treatment with 95% reduced side effects.
Key Investors
- • Johnson & Johnson Innovation
- • Roche Ventures
- • RA Capital
- • Flagship Pioneering
Founders
- • Dr. Jennifer Liu
- • Dr. Robert Kim
Previous Rounds
Market Impact
This funding round positions NanoMedicine Labs as a leader in the Biotech space, with the capital to accelerate innovation and expand their market presence. The investment reflects growing confidence in healthcare solutions and the company's potential to transform the industry.
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free